ArticleOncogene2025
FPR3 sustains the immunosuppression of tumor-associated macrophages and accelerates the progression of gastric adenocarcinoma.
Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Tissue-Resident Macrophage in Inflammation and Cancer.MedComm · 2026Review
- Targeting frizzled receptors (FZDs) for anti-tumor therapy: From orthosteric to allosteric inhibition.Acta pharmaceutica Sinica. B · 2026Review
- TMEM132A is associated with metabolic reprogramming, macrophage-oriented immune remodeling, and breast cancer progression.Clinical and experimental medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-associated macrophages (TAMs) play a critical role in promoting tumor progression and represent a promising target for immunotherapeutic intervention. However, the phenotypic characteristics and polarization dynamics of TAMs remain poorly understood, largely due to the complex cellular heterogeneity within the tumor microenvironment. In this study, we comprehensively characterize the heterogeneity of TAMs in gastric adenocarcinoma (GA), with a particular focus on immunosuppressive subsets. Our findings demonstrate that TAMs undergo multidirectional differentiation and exhibit diverse immunoregulatory functions. Among them, FPR3⁺ macrophages are identified as a distinct immunosuppressive population associated with poor patient prognosis. Functional assays using shRNA-mediated knockdown and specific agonists reveal that FPR3 regulates macrophage proliferation and polarization and is essential for TAM formation and maintenance. Mechanistically, FPR3 upregulates FZD7 and CCDC88C, leading to activation of the intracellular Wnt/PCP pathway and downstream JNK signaling, thereby promoting TAM development. Collectively, our study identifies FPR3 as a novel marker of immunosuppressive TAMs, elucidates its mechanistic role in macrophage plasticity, and offers new insights into potential therapeutic strategies for targeting the tumor microenvironment in GA.
Indexed as
Identifiers
40987893What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.